ELI LILLY AND COMPANY Net Fee Amt
ELI LILLY AND COMPANY (LLY) had Net Fee Amt of $1.24 million as of 2026-05-07, per its 424B2 filed 2026-05-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-08
- 2026-05-07: Net Fee Amt $1.24M.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-07 | $1.24M 424B2 · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |